GLP-1 2.5 mg Per ml w/B12 or w/o B12
- FormatInjectables
- SKUINJGLP1SEMA
Wholesale Pricing Available
Register for a wholesale account to view pricing, place bulk orders, and access volume discounts.
About this product
GLP-1 is a physician-formulated injectable supplied at 2.5 mg per ml, available with or without B12, developed under the direction of Dr. Sasson Moulavi for Lavi MD. Dosing is established by the provider and the product ships cold-chain.
Suggested use: Provider establish dose. Inject weekly
What It Does
Six Reasons Clinicians Recommend GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) is a naturally occurring gut hormone that regulates appetite, blood glucose, and digestion. Synthetic GLP-1 receptor agonists — the most widely studied class of weight and metabolic medications in modern medicine — mimic and amplify this hormone's effects to produce clinically meaningful and sustained improvements in body weight, glycemic control, and cardiovascular health.
How GLP-1 Receptor Agonists Work
Brain
Reduces appetite signals in the hypothalamus and reward centers
Stomach
Slows gastric emptying — extending fullness and reducing post-meal glucose spikes
Pancreas
Stimulates glucose-dependent insulin secretion and suppresses glucagon release
Heart & Vessels
Direct cardiovascular protective effects — reduces MACE risk independent of weight loss
Clinically Proven Weight Loss
GLP-1 receptor agonists are the most extensively studied weight loss medications in history. Semaglutide (Wegovy) demonstrated 15% mean body weight reduction in STEP trials. Tirzepatide (Zepbound) achieved up to 21% in SURMOUNT trials. These results — replicated across thousands of patients in randomized controlled trials — represent the largest pharmacological weight loss outcomes ever demonstrated before Retatrutide's Phase 2 data. Both are FDA-approved for chronic weight management.
Blood Sugar Control & Type 2 Diabetes Management
GLP-1 receptor agonists lower blood glucose through two distinct mechanisms — stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing post-meal glucagon release. This dual action produces significant reductions in fasting glucose and HbA1c without the hypoglycemia risk of insulin or sulfonylureas, since insulin secretion only occurs in response to elevated glucose. Multiple GLP-1 agents are FDA-approved as first-line type 2 diabetes treatments.
Cardiovascular Risk Reduction
GLP-1 receptor agonists are the only weight loss medications with proven cardiovascular mortality benefit in randomized controlled trials. The LEADER trial (liraglutide) and SELECT trial (semaglutide) demonstrated significant reductions in major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — independent of and in addition to their weight loss effects. GLP-1 receptors expressed directly in cardiac and vascular tissue contribute to this protection through anti-inflammatory and direct cardioprotective mechanisms.
Appetite Regulation & Reduced Food Cravings
GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signals — and GLP-1 receptor agonists significantly reduce appetite, food cravings, and the reward-driven eating that drives overconsumption. Clinical data shows reductions not just in total caloric intake but specifically in cravings for high-fat and high-sugar foods. Emerging research also suggests GLP-1 agonists reduce addictive behaviors broadly — with ongoing studies exploring applications in alcohol use disorder and compulsive eating.
Kidney & Liver Protection
GLP-1 receptor agonists demonstrate significant organ-protective effects beyond weight and glucose. In diabetic kidney disease, semaglutide reduced the risk of kidney disease progression by 24% in the FLOW trial — the first diabetes medication to show this level of renal protection. In non-alcoholic steatohepatitis (NASH), GLP-1 agents reduce liver fat, inflammation, and fibrosis — with semaglutide receiving Breakthrough Therapy designation for NASH treatment. These organ-level effects operate through both direct receptor activation and indirect improvements in metabolic health.
Neuroprotection & Emerging CNS Applications
GLP-1 receptors are expressed throughout the brain — and mounting evidence suggests GLP-1 receptor agonists reduce neuroinflammation, support neuronal survival, and may slow neurodegeneration. Semaglutide is currently in Phase 3 trials for Alzheimer's disease and Parkinson's disease prevention. Observational data from diabetic patient cohorts shows significantly lower rates of dementia and Parkinson's in GLP-1 users. These emerging neuroprotective applications may represent the next major indication for this already transformative class of medications.
Physician Supervision & Individualized Protocol Required
GLP-1 receptor agonists are titrated gradually to therapeutic dose to minimize gastrointestinal side effects — typically nausea, vomiting, and constipation in the early weeks. Dosing schedule, agent selection, and monitoring are determined individually by your prescribing physician based on your metabolic profile, medical history, and treatment goals. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN2. Available with a valid physician consultation only.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Available with a valid physician consultation only.
Formulated by Dr. Sasson Moulavi
Every Lavi MD peptide is developed under the direction of Dr. Sasson Moulavi, the physician behind the brand. Formulations are built to clinical specification, not sourced from anonymous suppliers.
Dr. Moulavi earned his Doctor of Medicine from the University of Toronto and completed postgraduate training at McGill University in Montreal. He holds Board Certification in Anti-Aging Medicine and Bariatric Medicine, and is a member of the American Academy of Anti-Aging Medicine and the American Society of Bariatric Physicians. With over three decades of clinical experience in bariatric, family, and anti-aging medicine, he serves as Medical Director and prescribing physician for Lavi MD, overseeing formulation standards and clinical protocols.
Simple, invoice-based ordering
No card is charged on this site. You build a request, we confirm it, and you pay a proper invoice. Built for how clinics and pharmacies actually buy.
Browse & build
Add products to your order request at wholesale pricing. No payment required.
Submit request
Send your request to our team. We review availability and confirm your order.
Get invoiced
You receive a QuickBooks invoice for the confirmed order and pay securely there.
Cold-chain ship
Once paid, your order is fulfilled and shipped cold-chain by our team.
Why Lavi MD
Not All Peptide Brands Are Equal
Most peptide suppliers prioritize volume over patients. We were built differently — by a physician, for patients.
Brands / Suppliers
Medical Director on Staff
Sasson Moulavi, MD
Dispensing Physician · Chayim Therapeutics, LLC
West Palm Beach, FL
"Every product we offer is something I would prescribe to my own patients. Our formulations are designed for clinical outcomes — not marketing claims."
How We Operate
Built by a Physician, Not a Marketing Team
Lavi MD was founded under physician supervision. Every formulation, every dose, every protocol is reviewed by Dr. Moulavi before it reaches a patient — not outsourced to a contract manufacturer with no clinical input.
We Limit Shipping Days to Protect Your Product
We only ship Monday and Tuesday. That's a deliberate decision — it ensures your order arrives before the weekend and never sits in a carrier facility over two days without refrigeration. Most brands don't think that far ahead.
We Treat You Like a Patient, Not an Order Number
Our team includes clinical staff who understand what you're taking and why. If something goes wrong with your order — a warm shipment, a missing component, a question about your protocol — we fix it. No automated runaround.
Proud Members of the
American Peptide Association
The American Peptide Association is the leading industry body advancing the science, safety, and standards of peptide research. Our membership reflects our unwavering commitment to purity, transparency, and responsible sourcing — giving you full confidence in every product you purchase.
